Navigation Links
Thrombosis Experts Present Update on Important New Developments in Anticoagulation Management
Date:10/29/2010

RESEARCH TRIANGLE PARK, N.C., Oct. 29 /PRNewswire/ -- Pharmaceutical Strategic Initiatives® announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.  The symposium titled Anticoagulation Management at the Crossroads –Addressing the Developments Impacting Future Decades was sponsored by Research Triangle Park, NC based Pharmaceutical Strategic Initiatives, LLC.  This interactive symposium was organized in collaboration with the Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, the North American Thrombosis Forum (NATF), and the International Union of Angiology (IUA).

Professor Jawed Fareed, Ph.D., Professor of Pathology and Pharmacology, Director of Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, was the chair for the program which also included presentations regarding emerging topics in anticoagulation management and for patients at risk of thrombosis and related disorders.  The distinguished faculty representing leading international institutions included Professor Samuel Goldhaber, MD from Brigham and Women's Hospital in Boston, MA, Professor Jeanine Walenga, Ph.D. from Loyola University Medical Center in Maywood, IL, Professor Benjamin Brenner from Rambam Health Care Campus in Haifa, Israel, Massimo Iacobelli, M.D. from Gentium, S.P.A. in Como Italy, Professor Selim Corbacioglu, M.D. from Children's Hospital Regensburg in Regensburg, Germany, Ilene Sussman, Ph.D. from the North American Thrombosis Forum in Boston, MA and Charles Carter, Pharm.D. from Pharmaceutical Strategic Initiatives, LLC in Research Triangle Park, NC.  The topics presented and discussed covered new treatment modalities for the prevention and treatment of patients at risk for thrombotic and vascular disorders including atrial fibrillation, acute coronary syndromes, diabetes, cancer and transplantation associated venous occlusive disorder.  In addition, the panel considered recent worldwide regulatory developments that are changing the landscape of anticoagulation therapy which includes the introduction of newer oral anticoagulants and generic versions of branded drugs.  The symposium was very well attended and a number of the hematology professionals who attended expressed their appreciation of this timely and informative session.

Pharmaceutical Strategic Initiatives LLC (PSI) is the premier provider of strategic clinical and regulatory consulting, priority comparative effectiveness and outcomes research, scientific content creation, opinion leader development and management to Academic Institutions, Pharmaceutical, Medical Device and Biotechnology companies. For 26 years, PSI has supported Educational Programs and Workshops, Medical Affairs, Regulatory Affairs, and Medical Marketing teams by developing successful business strategies and providing the implementation skills required to produce clear, measurable outcomes.  Charles A. Carter, Pharm.D., MBA is president of Pharmaceutical Strategic Initiatives, LLC.  PSI's offices are in Research Triangle Park, North Carolina.


'/>"/>
SOURCE Pharmaceutical Strategic Initiatives LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
3. The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment
4. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
5. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
6. Nanobiotechnology experts join forces to improve TB testing
7. Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics
8. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. What's Next for Stevia? Experts from GLG Life Tech Corp Share Views on Stevia's Future at Complimentary Webinar on 17 Feb.
11. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... , ... Sourcing custom glass or quartz parts can be a daunting task. ... execute your job can take many hours of emails, phone calls and on-line research. ... showcase the company’s capabilities and core custom categories, and enables you to start the ...
(Date:7/18/2017)... ... July 18, 2017 , ... G-CON today announced that ... Office for its Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile ... further expand the protection of G-CON’s R&D investments and validate the G-CON platform ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation ... the first phase of the Allotrope Framework for commercial use. , The Bio-IT ... to “not only elevate the critical role of information technology in modern biomedical ...
(Date:7/17/2017)... ... ... Whitehouse Laboratories is excited to announce that it has ... ISO 80369 standard test procedures. The ISO 80369 series of eight test standards ... this recent expansion, Whitehouse Labs becomes one of the only facilities in the ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):